Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Targeted Therapy 1Neoplasms 1Myeloproliferative Disorders 1Glioma 1Cholangiocarcinoma 1

Interventions

pembrolizumab 39Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Standard of Care 17Nivolumab 17Carboplatin 17Paclitaxel 15Exercise 15Gemcitabine 14atezolizumab 13Pemetrexed 13Cisplatin 13Radiotherapy 11Fluorouracil 11Doxorubicin 11Cetuximab 10130-nm albumin-bound paclitaxel 10durvalumab 9Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9Biopsy 9abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Prednisone 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × olutasidenib × 90 days × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡